HIV Clinical Trials

This study will evaluate the steady-state pharmacokinetics (PK) and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted darunavir (DRV/co) in HIV-1 infected antiretroviral treatment-experienced pediatric participants between the ages of 3 months to < 18 years of age. It will also evaluate the safety, tolerability, and efficacy of ATV/co ...

People with who have HIV-I are invited to participate in a research study of an investigational medication for high cholesterol that is being conducted by Montefiore Medical Center.

The purpose of the study is to see if there is a relationship to exposure to violence and HIV risk behaviors in young men who engage in same sex relationships. This is a one-time survey. Participation will take about 30 minutes. Participants may be asked if they are willing to ...

The primary objective of the study is to evaluate the longterm effect of EGRIFTA®, 2 mg once daily subcutaneously (SC), on the development of malignancies in subjects with human immunodeficiency virus (HIV) infection and concomitant abdominal lipohypertrophy. ClinicalTrials.gov Identifier: NCT01579695

Adding PRO 140 to current HIV therapy   Other Details:   https://clinicaltrials.gov/ct2/show/NCT02483078

Study of PRO 140 SubCutaneous as Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection. Volunteers switch from current drugs to PRO 140.   Other Details: https://clinicaltrials.gov/ct2/show/NCT02859961

Researchers at the University of Kentucky are conducting a study to learn how two different medications that are used to treat opioid use disorder affect the health of patients who are HIV-positive. We will be learning about a drug called Extended-Release Naltrexone. We hope to find out if using the ...

This randomized phase III trial compares topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is ...

GPS is a sexual health promotion and HIV prevention peer-delivered counselling program. The GPS program has 4 parts: information provision about HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care. The adaptation grant has three goals: 1) to establish a multi-region and ...

The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV and hepatitis B virus (HBV) treatment naive, HIV-1 and HBV co-infected adults.